Debt-laden Teva weighs $2B women's health sale: report by Carly Helfand Sunday, April 9, 2017 Teva execs may have zeroed in on their first big revamp move since CEO Erez Vigodman's sudden exit.
Teva CEO Vigodman exits, piling uncertainty onto the struggling drugmaker by Carly Helfand Tuesday, February 7, 2017 So long, Erez Vigodman. After a brutal 2016 and start to 2017 for Teva, the company’s CEO is stepping down.
How did Teva overestimate 2017 sales by $1B? CEO explains by Carly Helfand Tuesday, January 10, 2017 On Monday at the J.P. Morgan Healthcare Conference, Teva CEO Erez Vigodman explained just how the company arrived at the off-base guidance it cut last week by more than $1 billion.
